Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

Core Viewpoint - Aquestive Therapeutics, Inc. plans to conduct an underwritten public offering of its common stock, with a potential additional 15% of shares available for purchase by underwriters [1][2] Group 1: Offering Details - The public offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1] - Leerink Partners and Piper Sandler are the joint bookrunning managers, while Oppenheimer & Co. serves as the lead manager for the offering [2] Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance the development and commercialization of the product pipeline, including Anaphylm™ Sublingual Film and Libervant™ Buccal Film, as well as for working capital and general corporate purposes [2] Group 3: Company Overview - Aquestive Therapeutics focuses on innovative science and delivery technologies to improve patient lives, with a pipeline that includes treatments for severe allergic reactions and central nervous system diseases [5] - The company has five commercialized products and collaborates with other pharmaceutical companies to bring new molecules to market using proprietary technologies [5]